Theseus Pharmaceuticals, Inc. (THRX): Price and Financial Metrics
THRX Price/Volume Stats
| Current price | $4.06 | 52-week high | $12.37 |
| Prev. close | $4.06 | 52-week low | $2.05 |
| Day low | $4.06 | Volume | 3,123,100 |
| Day high | $4.07 | Avg. volume | 592,167 |
| 50-day MA | $3.96 | Dividend yield | N/A |
| 200-day MA | $4.97 | Market Cap | 179.57M |
THRX Stock Price Chart Interactive Chart >
Theseus Pharmaceuticals, Inc. (THRX) Company Bio
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest THRX News From Around the Web
Below are the latest news stories about THESEUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate THRX as an investment opportunity.
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of b |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning! |
Theseus (THRX) Up 57% in a Month on Strategic Restructuring PlanTheseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%. |
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCOn November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Compan |
Theseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce ReductionCompany Announces Significant Corporate Restructuring to Enhance Shareholder Value |
THRX Price Returns
| 1-mo | N/A |
| 3-mo | 1.50% |
| 6-mo | 88.84% |
| 1-year | -61.70% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 0.25% |
| 2023 | -18.67% |
| 2022 | -60.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...